about Details  1/18 Figure 3.75" Fit Unpainted Sculpt Head Landa Hans Generals German The Scale Action Figures


  1. Home
  2. about Details  1/18 Figure 3.75" Fit Unpainted Sculpt Head Landa Hans Generals German The Scale
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Details about   1/18 Scale The German Generals Hans Landa Head Sculpt Unpainted Fit 3.75" Figure
Condition: New: A brand-new, unused, unopened, undamaged item (including handmade items). See the seller's Brand: Unbranded
Bodypart Type: 1:18 MPN: Does Not Apply
Packaging: Without Packaging Country/Region of Manufacture: China
Age Level: Head Scale: 1:18
Material: Resin Non-Domestic Product: No
UPC: Does Not Apply


published on tue nov 09 2021

about Details  1/18 Figure 3.75" Fit Unpainted Sculpt Head Landa Hans Generals German The Scale Action Figures

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

about Details  1/18 Figure 3.75" Fit Unpainted Sculpt Head Landa Hans Generals German The Scale Action Figures

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS